Zoetis (NYSE:ZTS) is scheduled to announce its earnings results before the market opens on Thursday, February 15th. Analysts expect the company to announce earnings of $0.66 per share for the quarter.
Shares of Zoetis (NYSE:ZTS) opened at $73.86 on Thursday. The company has a market capitalization of $35,990.00, a price-to-earnings ratio of 38.87, a PEG ratio of 1.63 and a beta of 1.07. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. Zoetis has a 12-month low of $52.00 and a 12-month high of $80.13.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, January 19th will be given a $0.126 dividend. This represents a $0.50 annualized dividend and a dividend yield of 0.68%. The ex-dividend date is Thursday, January 18th. This is a boost from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio (DPR) is 26.32%.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/02/08/zoetis-zts-set-to-announce-quarterly-earnings-on-thursday.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.